Recently, the FDA approved three new therapeutic strategies for first-line therapy in metastatic NSCLC patients: atezolizumab in patients with ≥50% of TC with PD-L1 expression (Impower-110 study); combination therapy with nivolumab and ipilimumab in patients with ≥1% of PD-L1 positive TC (CheckMate-227 study); and combination therapy with nivolumab, ipilimumab, and chemotherapy in patients regardless of PD-L1 expression on TC (CheckMate-9LA study) (29–33). Here, CD274 is linked to non-small cell lung carcinoma.